• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

疾病认知、药物认知、抗凝相关生活质量与国际标准化比值(INR)控制之间的关联:转换研究的见解

Associations between illness beliefs, medication beliefs, anticoagulation-related quality of life, and INR control: Insights from the Switching Study.

作者信息

Bartoli-Abdou John K, Patel Jignesh P, Xie Rosa, Dzahini Olubanke, Vadher Bipin, Brown Alison, Roberts Lara N, Patel Raj K, Arya Roopen, Auyeung Vivian

机构信息

Institute of Pharmaceutical Science King's College London London UK.

King's Thrombosis Centre Department of Haematological Medicine King's College Hospital NHS Foundation Trust London UK.

出版信息

Res Pract Thromb Haemost. 2018 Jun 7;2(3):497-507. doi: 10.1002/rth2.12116. eCollection 2018 Jul.

DOI:10.1002/rth2.12116
PMID:30046754
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6046584/
Abstract

BACKGROUND

Anticoagulation control with vitamin-K antagonists (VKAs) in patients with atrial fibrillation (AF) or venous thromboembolism (VTE) can be measured using time in therapeutic range (TTR), where TTR >65% is considered good and low TTR may be associated with low adherence.

METHODS

This cross-sectional observational study compared illness beliefs, treatment beliefs, and treatment satisfaction of patients with TTR >75% and TTR <50% using validated tools to determine their association with TTR. Adults requiring chronic VKA therapy were recruited from 2 hospital anticoagulation clinics in London, UK.

RESULTS

311 patients with TTR >75% and 214 with TTR <50% were recruited. TTR >75% patients had been taking warfarin on average over 2 years longer than TTR <50% patients (<.001). Statistically significant differences in beliefs were found in all subscales other than in treatment control, general harm, and general overuse. Cluster analysis determined there were 4 distinct clusters of beliefs among patients. Multivariate binary logistic regression found VTE patients were least likely to have poor TTR (OR = 0.49; 95% CI 0.29, 0.77). Patients in the "cautious of therapy and fearful of illness" cluster were most likely to have low TTR (OR = 4.75; 95% CI 2.75, 8.77).

CONCLUSION

Illness perceptions, medication beliefs and treatment satisfaction were associated with INR control. VTE patients and those who were accepting of both illness and treatment were most likely to have optimal INR control.

摘要

背景

心房颤动(AF)或静脉血栓栓塞(VTE)患者使用维生素K拮抗剂(VKA)进行抗凝控制时,可通过治疗范围内时间(TTR)来衡量,其中TTR>65%被认为是良好的,而低TTR可能与依从性低有关。

方法

这项横断面观察性研究使用经过验证的工具比较了TTR>75%和TTR<50%患者的疾病信念、治疗信念和治疗满意度,以确定它们与TTR的关联。从英国伦敦的2家医院抗凝门诊招募需要长期VKA治疗的成年人。

结果

招募了311名TTR>75%的患者和214名TTR<50%的患者。TTR>75%的患者服用华法林的平均时间比TTR<50%的患者长2年多(<.001)。除治疗控制、一般危害和一般过度使用外,在所有子量表中均发现信念存在统计学显著差异。聚类分析确定患者中存在4种不同的信念聚类。多变量二元逻辑回归发现VTE患者TTR差的可能性最小(OR=0.49;95%CI 0.29,0.77)。“对治疗谨慎且对疾病恐惧”聚类中的患者TTR低的可能性最大(OR=4.75;95%CI 2.75,8.77)。

结论

疾病认知、药物信念和治疗满意度与国际标准化比值(INR)控制相关。VTE患者以及那些接受疾病和治疗的患者最有可能实现最佳INR控制。

相似文献

1
Associations between illness beliefs, medication beliefs, anticoagulation-related quality of life, and INR control: Insights from the Switching Study.疾病认知、药物认知、抗凝相关生活质量与国际标准化比值(INR)控制之间的关联:转换研究的见解
Res Pract Thromb Haemost. 2018 Jun 7;2(3):497-507. doi: 10.1002/rth2.12116. eCollection 2018 Jul.
2
Long-term adherence to direct acting oral anticoagulants and the influence of health beliefs after switching from vitamin-K antagonists: Findings from the Switching Study.长期坚持直接口服抗凝剂和从维生素 K 拮抗剂转换后的健康信念的影响:来自 Switching 研究的发现。
Thromb Res. 2021 Dec;208:162-169. doi: 10.1016/j.thromres.2021.11.003. Epub 2021 Nov 15.
3
Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression.维生素 K 拮抗剂控制质量与心房颤动患者结局的关系:一项荟萃分析和荟萃回归。
Thromb J. 2014 Jun 24;12:14. doi: 10.1186/1477-9560-12-14. eCollection 2014.
4
Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.止血专家对接受维生素K拮抗剂治疗的心房颤动患者的慢性抗凝控制质量及在治疗范围内的时间进行评估:TERRA注册研究:阿根廷共和国的目标时间范围。
Clin Appl Thromb Hemost. 2017 Jul;23(5):445-453. doi: 10.1177/1076029615623378. Epub 2016 Jan 5.
5
Quality control of oral anticoagulation with vitamin K antagonists in primary care patients in Poland: a multi-centre study.波兰初级保健患者中维生素 K 拮抗剂的口服抗凝治疗质量控制:一项多中心研究。
Kardiol Pol. 2018;76(4):764-769. doi: 10.5603/KP.2018.0011. Epub 2018 Jan 9.
6
Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score.华法林抗凝治疗的心房颤动患者抗凝控制质量的影响因素:SAMe-TT₂R₂评分。
Chest. 2013 Nov;144(5):1555-1563. doi: 10.1378/chest.13-0054.
7
Quality of warfarin management in primary care: Determining the stability of international normalized ratios using a nationally representative prospective cohort.初级保健中华法林管理的质量:使用全国代表性的前瞻性队列确定国际标准化比值的稳定性。
Can Fam Physician. 2019 Jun;65(6):416-425.
8
Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation.SAMe-TT₂R₂ 评分与房颤患者抗凝治疗效果不佳、卒中、临床相关出血和死亡率的关系。
Chest. 2014 Sep;146(3):719-726. doi: 10.1378/chest.13-2976.
9
Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland.322例心房颤动患者维生素K拮抗剂口服抗凝治疗质量——来自瑞士东部一项调查的真实数据
Swiss Med Wkly. 2017 Oct 6;147:w14503. doi: 10.4414/smw.2017.14503. eCollection 2017.
10
Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national and multicentre SULTAN registry.影响新使用维生素 K 拮抗剂的房颤患者抗凝质量的因素:来自全国和多中心 SULTAN 登记研究的见解。
Europace. 2022 Jan 4;24(1):4-11. doi: 10.1093/europace/euab131.

引用本文的文献

1
Balancing the risks of recurrent venous thromboembolism and bleeding with extended anticoagulation: oh, for a crystal ball!权衡延长抗凝治疗时复发性静脉血栓栓塞和出血的风险:哦,要是能有个水晶球就好了!
Res Pract Thromb Haemost. 2024 Jan 18;8(1):102316. doi: 10.1016/j.rpth.2024.102316. eCollection 2024 Jan.
2
Adherence, belief, and knowledge about oral anticoagulants in patients with bioprosthetic heart valve replacement: a cross-sectional study.生物人工心脏瓣膜置换患者口服抗凝剂的依从性、信念和知识:一项横断面研究。
Front Pharmacol. 2023 Jul 12;14:1191006. doi: 10.3389/fphar.2023.1191006. eCollection 2023.
3
Use of direct oral anticoagulants in primary care: a qualitative study integrating patient and practitioner perspectives.基层医疗中直接口服抗凝剂的使用:一项整合患者和从业者观点的定性研究。
BJGP Open. 2022 Dec 20;6(4). doi: 10.3399/BJGPO.2021.0226. Print 2022 Dec.
4
The Transcultural Adaptation and Validation of the Chinese Version of the Duke Anticoagulation Satisfaction Scale.《杜克抗凝满意度量表中文版的跨文化调适与验证》
Front Pharmacol. 2022 Feb 23;13:790293. doi: 10.3389/fphar.2022.790293. eCollection 2022.
5
Patients' and clinicians' perceptions of oral anticoagulants in atrial fibrillation: a systematic narrative review and meta-analysis.患者和临床医生对心房颤动中口服抗凝剂的看法:系统叙述性综述和荟萃分析。
BMC Fam Pract. 2021 Dec 22;22(1):254. doi: 10.1186/s12875-021-01590-x.
6
Factors Associated with Medication Beliefs in Patients with Parkinson's Disease: A Cross-Sectional Study.帕金森病患者用药信念的相关因素:一项横断面研究。
J Mov Disord. 2021 May;14(2):133-143. doi: 10.14802/jmd.20147. Epub 2021 May 3.
7
Sense of Coherence and Quality of Life in Patients Treated with Antivitamin K Oral Anticoagulants: A Cross-Sectional Study.抗维生素 K 口服抗凝剂治疗患者的整体感和生活质量:一项横断面研究。
Int J Environ Res Public Health. 2021 Feb 9;18(4):1668. doi: 10.3390/ijerph18041668.
8
Health-related quality of life in nonvalvular atrial fibrillation patients with controlled or uncontrolled anticoagulation status.非瓣膜性心房颤动患者抗凝控制或未控制状态下的健康相关生活质量。
Health Qual Life Outcomes. 2020 Dec 11;18(1):383. doi: 10.1186/s12955-020-01563-1.
9
Warfarin therapy in atrial fibrillation: assessment of patient knowledge of risks and benefits.心房颤动的华法林治疗:患者对风险和益处的认知评估
J Community Hosp Intern Med Perspect. 2020 Jun 14;10(3):179-187. doi: 10.1080/20009666.2020.1767270.
10
Validation and psychometric properties of the Maltese version of the Duke Anticoagulation Satisfaction Scale (DASS).马耳他语版杜克抗凝满意度量表(DASS)的效度及心理测量特性
Psychol Res Behav Manag. 2019 Aug 28;12:741-752. doi: 10.2147/PRBM.S216617. eCollection 2019.

本文引用的文献

1
Exploration of adherence and patient experiences with DOACs one year after switching from vitamin-K antagonists- insights from the switching study.从维生素 K 拮抗剂转换一年后,直接口服抗凝剂的依从性和患者体验探索——转换研究的见解。
Thromb Res. 2018 Feb;162:62-68. doi: 10.1016/j.thromres.2017.12.021. Epub 2018 Jan 2.
2
Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation.心房颤动患者抗凝治疗的教育与行为干预措施
Cochrane Database Syst Rev. 2017 Apr 5;4(4):CD008600. doi: 10.1002/14651858.CD008600.pub3.
3
Making sense of Cronbach's alpha.理解克朗巴哈系数。
Int J Med Educ. 2011 Jun 27;2:53-55. doi: 10.5116/ijme.4dfb.8dfd.
4
Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants.心房颤动患者口服抗凝治疗的依从性。聚焦于非维生素K拮抗剂口服抗凝药。
Thromb Haemost. 2017 Jan 26;117(2):209-218. doi: 10.1160/TH16-10-0757. Epub 2016 Nov 10.
5
Anticoagulated patient's perception of their illness, their beliefs about the anticoagulant therapy prescribed and the relationship with adherence: impact of novel oral anticoagulant therapy - study protocol for The Switching Study: a prospective cohort study.接受抗凝治疗患者对自身疾病的认知、对所开抗凝治疗的信念及其与依从性的关系:新型口服抗凝治疗的影响——转换研究的研究方案:一项前瞻性队列研究
BMC Hematol. 2016 Aug 23;16(1):22. doi: 10.1186/s12878-016-0061-9. eCollection 2016.
6
Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences.维生素K拮抗剂的使用:实现和维持目标国际标准化比值(INR)范围存在困难的证据及后续后果。
Thromb J. 2016 Jun 13;14:14. doi: 10.1186/s12959-016-0088-y. eCollection 2016.
7
Adherence to long-term anticoagulation treatment, what is known and what the future might hold.长期抗凝治疗的依从性,已知的和未来可能的情况。
Br J Haematol. 2016 Jul;174(1):30-42. doi: 10.1111/bjh.14134. Epub 2016 May 12.
8
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.更新的欧洲心脏节律协会实用指南:非维生素 K 拮抗剂抗凝剂在非瓣膜性心房颤动患者中的应用。
Europace. 2015 Oct;17(10):1467-507. doi: 10.1093/europace/euv309. Epub 2015 Aug 31.
9
Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation.维生素K拮抗剂抗凝不足与心房颤动患者的主要不良心血管事件相关。
Int J Cardiol. 2015 Dec 15;201:513-6. doi: 10.1016/j.ijcard.2015.08.054. Epub 2015 Aug 5.
10
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial.患者对口服利伐沙班与标准治疗肺栓塞的治疗满意度报告:EINSTEIN PE 试验结果。
Thromb Res. 2015 Feb;135(2):281-8. doi: 10.1016/j.thromres.2014.11.008. Epub 2014 Nov 18.